Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two of BioStem’s patent applications.
Jason Matuszewski, Chief Executive Officer of BioStem, stated: “BioStem is actively expanding its patent portfolio to accelerate product innovation and to drive development of new products that continue to elevate the standards of wound care. These newly granted patents will play a pivotal role in the development of next-generation products, further solidifying our position as a leader in the industry. BioStem’s robust intellectual property portfolio spans the wound care landscape, providing strong protection as we continue to introduce breakthrough solutions to the market and consider other regulatory pathways to strengthen our product positioning."
The USPTO has issued a Notice of Allowance for the following applications:
No. 18/593,225:MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN
The patent is directed to novel and inventive micronized human placental compositions for wound care. The unique method of preparing BioStem’s compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue. These compositions can be used to develop products for wound packing, treatment of wounds having irregular surfaces/boundaries, weeping wounds, and dental/ oral wounds. These micronized compositions could even be integrated into a therapeutic bandage to support healing of a topical wound.
No. 18/290,914: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF
The patent is directed to novel and inventive human placental allograft compositions manufactured with the BioRetain® process. The unique method of preparing these allograft compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue thereby facilitating and supporting wound treatment when compared with conventional human placental allografts for the treatment of, for example, diabetic foot ulcers, dental wounds, and/or other topical wounds.
Mr.Matuszewski added: “The added protection for our proprietary BioREtain processing method bolsters the differentiation of this technology in the marketplace. We also intend to demonstrate the benefits of those differences to patients with ongoing benchtop and clinical studies.”
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2 ™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
